Tonghuashun (300033) Financial Research Center, April 12cryptogamelikeaxieinfinitySome investors asked Watson Biotech (300142)(300142). According to the company's September 2022 announcement, the company's nine-valent HPV vaccine has begun clinical phase III in 2022. Market rumors compare the immunogenicity of the company's nine-valent HPV vaccine with similar vaccinescryptogamelikeaxieinfinityThe key Phase III clinical trial of the company's nine-valent HPV vaccine has not yet been opened. What is the actual clinical progress and relevant data of the company's nine-valent HPV vaccine in Phase III clinical trials?

The company replied, Dear Investor, Hello! The company is currently maintaining close communication with CDE based on the clinical development plan of 9-valent HPV products, and actively striving to conduct clinical research on protective effectiveness with optimal strategies. Thank you!